**7. Conclusions**

The field of viscoelastic hemostatic assays is rapidly growing and generating significant clinical studies, academic research, and industry funding. Whilst older devices have been available for several decades, new technologies are being introduced that promise to make viscoelastic testing more readily available in a wider range of clinical environments. New assays are being developed to give clinicians information about their patients' hemostasis that have never been available before. New indications that have been recently approved, or are currently under investigation, include trauma, interventional cardiology, extracorporeal cardiac assist, obstetrics and anti-coagulation therapy monitoring. The ability of viscoelastic hemostatic assays to deliver clear and readily actionable information about a patient's overall hemostatic status will continue to improve patient care in the years ahead; however, newer technologies and devices will have to demonstrate their clinical e ffectiveness.

**Author Contributions:** Initial literature search and review outline was generated by J.H. and M.M. M.M. drafted the initial manuscript with support from J.H. J.H., J.D.D. and M.M. reviewed the manuscript and provided substantial contributions to the final version. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Acknowledgments:** The authors thank Meridian HealthComms, Plumley, UK for providing formatting and editorial assistance in the submission process, which was funded by Haemonetics, SA, Signy, Switzerland, in accordance with Good Publication Practice (GPP3).

**Conflicts of Interest:** All authors are employees of Haemonetics, the manufacturer of the TEG ® technology.
